Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns
AI Summary
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has updated its guidance regarding weight-loss jabs containing GLP-1 medications, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), due to a small risk of severe acute pancreatitis. This follows an increase in reports to the MHRA yellow card scheme, which monitors adverse reactions to medications. From early 2024 to early 2025, approximately 1.6 million adults in England, Wales, and Scotland used these medications. While pancreatitis is listed as an uncommon reaction, the MHRA has received over 1,100 reports of acute and chronic pancreatitis related to semaglutide or tirzepatide, with 17 reported fatalities. The MHRA advises patients and healthcare professionals to be aware of symptoms like severe abdominal pain, nausea, and fever, and to report any concerns.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).
Topic Connections
Explore how the topics in this article connect to other news stories